Not available
Quote | EPAM Systems Inc. (NYSE:EPAM)
Last: | $181.91 |
---|---|
Change Percent: | 0.18% |
Open: | $182.76 |
Close: | $181.91 |
High: | $183.47 |
Low: | $181.07 |
Volume: | 565,453 |
Last Trade Date Time: | 06/25/2024 03:00:00 am |
News | EPAM Systems Inc. (NYSE:EPAM)
2024-06-25 11:05:30 ET More on Markets UBS: ‘An economic slowdown is underway’ Oppenheimer spotlights top buy/sell ideas for mid and small cap names Stagflation Risks Fade, But Recession Odds Rise S&P 500 Investors Looking For Direction ...
2024-06-25 10:29:34 ET More on S&P 500 Index: Odds For A Soft Landing Improve S&P 6300? Is That Outside The Realm Of Possibility? Nervous Calm Hangs Over The Markets Nasdaq, S&P, Dow are mixed after selloff in tech stocks Is the Nvidia-led...
Message Board Posts | EPAM Systems Inc. (NYSE:EPAM)
Subject | By | Source | When |
---|---|---|---|
$EPAM Price gaining up | stocktrademan | investorshub | 05/03/2023 3:00:30 PM |
$EPAM what do you make of this data? | stocktrademan | investorshub | 04/22/2023 7:54:38 PM |
MomentumIts now | HokieHead | investorshub | 04/21/2023 1:34:11 PM |
The now last trade up | HokieHead | investorshub | 04/06/2023 8:53:17 PM |
Sub 200 today | Actualfactual | investorshub | 02/28/2022 6:55:37 PM |
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Reliance Global Group Inc. (RELI) rose 76.2% to $0.3911 on volume of 383,719,808 shares NLS Pharmaceutics Ltd. (NLSP) rose 82.1% to $0.2701 on volume of 302,290,803 shares NVIDIA Corporation (NVDA) rose 3.5% to $135.58 on volume of 28...
A look at the top 10 most actives in the United States NLS Pharmaceutics Ltd. (NLSP) rose 156.2% to $0.38 on volume of 125,047,059 shares Reliance Global Group Inc. (RELI) rose 210.8% to $0.69 on volume of 110,427,102 shares Mustang Bio Inc. (MBIO) rose 53.3% to $1.15 on volume of 87,727,...
EPAM Acquires Odysseus -- to transform the Life Sciences Value Chain with Advanced Analytics, Data Methods and AI PR Newswire Improving life sciences research, clinical studies and post-market surveillance powered by data and AI NEWTOWN, Pa. , June 13, 2024 ...